Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 May;67(5):547-57.
doi: 10.1111/j.1365-2125.2009.03391.x. Epub 2009 Feb 11.

Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus

Nadia Rashid Al Mazroui  1 , Mostafa Mohamed Kamal, Naserdeen Mehana Ghabash, Targ Ahmed Yacout, Prashant Laxman Kole, James C McElnay
Affiliations
Randomized Controlled Trial

Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus

Nadia Rashid Al Mazroui et al. Br J Clin Pharmacol. 2009 May.

Abstract

Aims: To examine the influence of a pharmaceutical care programme on disease control and health-related quality of life in Type 2 diabetes patients in the United Arab Emirates.

Methods: A total of 240 Type 2 diabetes patients were recruited into a randomized, controlled, prospective clinical trial with a 12-month follow-up. A range of clinical measures, medication adherence and health-related quality of life (Short Form 36) were evaluated at baseline and up to 12 months. Intervention group patients received pharmaceutical care from a clinical pharmacist, whereas control group patients received their usual care from medical and nursing staff. The primary outcome measure was change in HbA(1c). British National Formulary and Framingham scoring methods were used to estimate changes in 10-year coronary heart disease risk scores in all patients.

Results: A total of 234 patients completed the study. Significant reductions (P < 0.001) in mean values (baseline vs. 12 months; 95% confidence interval) of HbA(1c)[8.5% (8.3, 8.7) vs. 6.9% (6.7, 7.1)], systolic [131.4 mmHg (128.1, 134.7) vs. 127.2 mmHg (124.4, 130.1)] and diastolic blood pressure [85.2 mmHg (83.5, 86.8) vs. 76.3 mmHg (74.9, 77.7)] were observed in the intervention group; no significant changes were noted in the control group. The mean Framingham risk prediction score in the intervention group was 10.56% (9.7, 11.4) at baseline; this decreased to 7.7% (6.9, 8.5) (P < 0.001) at 12 months but remained unchanged in the control group.

Conclusions: The pharmaceutical care programme resulted in better glycaemic control and reduced cardiovascular risk scores in Type 2 diabetes patients over a 12-month period.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart relating to various phases of randomized controlled clinical trial
See this image and copyright information in PMC

References

    1. Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia. 2002;45:S18–22. - PubMed
    1. Abuissa H, Bel DS, O’Keefe JH., Jr Strategies to prevent type 2 diabetes. Curr Med Res Opin. 2005;21:1107–14. - PubMed
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL., Jr Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52. - PubMed
    1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–19. - PMC - PubMed
    1. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 1993;11:319–25. - PubMed

Publication types

MeSH terms